To play devils advocate here. Anyone have thoughts on what effect unsuccessful ph2 trials would have on the future of Neuren? Would Acadia still take us out? Share price doesn't look to have ph2 baked in. Would we see big pullbacks initially? Would we have to explore other possible areas for treatment?
a.
Share Price, page-6357
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.61 |
Change
0.400(2.63%) |
Mkt cap ! $1.996B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $2.650M | 169.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 2637 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.62 | 248 | 14 |
View Market Depth
| Last trade - 13.03pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |